Questions about this study?
The HopeStage team will email you.
WithdrawnNCT07169162
ADZENYS XR-ODT™ for ADHD
Medication studyAges 4–5United States
Understand this study
Who could participate?
Listed age limits: 4 years to 5 years.
- Listed locations
- Las Vegas, United StatesSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: May 2019
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Aytu BioPharma, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 4 Years to 5 Years
- Official registry ID
- NCT07169162
- Official title
Show the full official title
A Randomized, Double-blind, Parallel, Placebo-controlled, Flexible-dose Study of ADZENYS XR-ODT™ in Children Aged 4 to Less Than 6 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
WithdrawnLas Vegas
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Aytu BioPharma, Inc.
Does this study involve medication?
Yes. The study involves medication, including ADZENYS XR-ODT and Placebo Oral Tablet.
Who can participate?
Listed age limits: 4 years to 5 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me